Survival outcomes following autologous stem cell transplant with melphalan 140mg/m
Document Type
Article
Publication Title
Leukemia & lymphoma
Abstract
The standard preparative regimen for autologous stem cell transplant (ASCT) in multiple myeloma (MM) is 200 mg/m
First Page
1315
Last Page
1321
DOI
10.1080/10428194.2023.2213366
Publication Date
1-1-2023
Recommended Citation
Sharma, Nidhi; Benson, Evan; Zhao, Qiuhong; Nunnelee, Jordan; Cottini, Francesca; Elder, Patrick; Rosko, Ashley; Bumma, Naresh; Khan, Abdullah; Umyarova, Elvira; Devarakonda, Srinivas; Efebera, Yvonne A; and Benson, Don M, "Survival outcomes following autologous stem cell transplant with melphalan 140mg/m" (2023). Oncology Articles. 8.
https://scholarlyworks.ohiohealth.com/oncology-articles/8
COinS